APGE: Apogee Therapeutics, Inc. Stock

by  •  • Comments Off on APGE: Apogee Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 2,117.05
Enterprise Value ($M) 2,010.13
Book Value ($M) 673.36
Book Value / Share 11.55
Price / Book 3.14
NCAV ($M) 480.73
NCAV / Share 8.25
Price / NCAV 4.40

Profitability (mra)
Return on Invested Capital (ROIC) -0.30
Return on Assets (ROA) -0.25
Return on Equity (ROE) -0.26

Liquidity (mrq)
Quick Ratio 15.82
Current Ratio 15.82

Balance Sheet (mrq) ($M)
Current Assets 521.53
Assets 714.16
Liabilities 40.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -216.87
Net Income -182.15

Cash Flow Statement (mra) ($M)
Cash From Operations -171.17
Cash from Investing -300.46
Cash from Financing 495.11

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-12 13G/A Wellington Management Group Llp 11.90 13.94
02-14 13G Rtw Investments, Lp 6.00
11-14 13G/A Ra Capital Management, L.p. 3.40 -0.81
11-14 13G/A Deep Track Capital, LP 2.22 -56.96
11-14 13G Driehaus Capital Management Llc 5.63
11-12 13G/A Fmr Llc 16.67 49.49
11-08 13G BlackRock, Inc. 6.60 0.00
11-04 13G/A Access Industries Management, Llc 4.87 12.88

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures Item 1.
2025-03-03 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-02 112,337 658,541 17.06
2025-05-30 72,127 445,531 16.19
2025-05-29 54,082 335,736 16.11
2025-05-28 77,114 474,327 16.26

(click for more detail)

Similar Companies
ADMA – ADMA Biologics, Inc. ALT – Altimmune, Inc.
ANIP – ANI Pharmaceuticals, Inc. APLT – Applied Therapeutics, Inc.
AQST – Aquestive Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io